Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination (Q34325573)

1 August 2017

1 reference

title

Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination (English)

1 reference

1 August 2017

Sheryl Zelenitsky

0 references

George G Zhanel

1 reference

1 August 2017

James A Karlowsky

1 reference

1 August 2017

Christopher D Lawson

1 reference

1 August 2017

Heather Adam

1 reference

1 August 2017

Frank Schweizer

1 reference

1 August 2017

Philippe R S Lagacé-Wiens

1 reference

1 August 2017

Andrew Denisuik

1 reference

1 August 2017

Ethan Rubinstein

1 reference

1 August 2017

Alfred S Gin

1 reference

1 August 2017

Daryl J Hoban

1 reference

1 August 2017

Joseph P Lynch

1 reference

1 August 2017

publication date

1 February 2013

1 reference

1 August 2017

1 reference

1 August 2017

1 reference

1 August 2017

1 reference

1 August 2017

page(s)

159-177

1 reference

Infections with extended-spectrum beta-lactamase-producing enterobacteriaceae: changing epidemiology and drug treatment choices

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0013-7

Alarming β-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0013-7

The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0013-7

Has the era of untreatable infections arrived?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0013-7

MYSTIC Europe 2007: activity of meropenem and other broad-spectrum agents against nosocomial isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0013-7

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0013-7

Antimicrobial susceptibility of global inpatient urinary tract isolates of Escherichia coli: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program: 2009–2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0013-7

Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0013-7

The cephalosporin antimicrobial agents: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0013-7

Role of penicillin-binding proteins in bacterial cell morphogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0013-7

Peptidoglycan structure and architecture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0013-7

The penicillin-binding proteins: structure and role in peptidoglycan biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0013-7

Resistance to beta-lactam antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0013-7

Epidemiological expansion, structural studies, and clinical challenges of new β-lactamases from gram-negative bacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0013-7

The structure of β-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0013-7

A standard numbering scheme for the class A beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0013-7

ampC cephalosporinase of Escherichia coli K-12 has a different evolutionary origin from that of beta-lactamases of the penicillinase type

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0013-7

Precise insertion of antibiotic resistance determinants into Tn21-like transposons: nucleotide sequence of the OXA-1 beta-lactamase gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0013-7

Updated functional classification of beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0013-7

A functional classification scheme for beta-lactamases and its correlation with molecular structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0013-7

Molecular analysis of beta-lactamase structure and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0013-7

Serine beta-lactamases and penicillin-binding proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0013-7

Zinc and antibiotic resistance: metallo-beta-lactamases and their synthetic analogues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0013-7

Extended-spectrum and inhibitor-resistant TEM-type beta-lactamases: mutations, specificity, and three-dimensional structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0013-7

NXL104 Irreversibly Inhibits the β-Lactamase from Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0013-7

Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0013-7

Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0013-7

In vitro activity of AVE1330A, an innovative broad-spectrum non-beta-lactam beta-lactamase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0013-7

Characterization of β-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0013-7

In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0013-7

In vitro activity of NXL104 in combination with beta-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0013-7

Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0013-7

Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0013-7

In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0013-7

Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-Producing Enterobacteriaceae

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0013-7

In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0013-7

In Vitro Activity of Ceftazidime Combined with NXL104 versus Pseudomonas aeruginosa Isolates Obtained from Patients in Canadian Hospitals (CANWARD 2009 Study)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0013-7

Antimicrobial susceptibility of 15,644 pathogens from Canadian hospitals: results of the CANWARD 2007–2009 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0013-7

Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0013-7

NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum beta-lactamases and carbapenemases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0013-7

In vitro activity of the {beta}-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0013-7

In Vitro Activity of Ceftazidime-NXL104 against 396 Strains of β-Lactamase-Producing Anaerobes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0013-7

Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0013-7

Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0013-7

Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized stud

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0013-7

beta-Lactam antibiotics: structural relationships affecting in vitro activity and pharmacologic properties

21 January 2018

1 reference

12 December 2020

Mode of action of ceftazidime: affinity for the penicillin-binding proteins of Escherichia coli K12, Pseudomonas aeruginosa and Staphylococcus aureus

1 reference

12 December 2020

Beta-lactamase stability of cefoxitin in comparison with other beta-lactam compounds

1 reference

12 December 2020

Ceftizoxime and other third-generation cephalosporins: structure-activity relationships

1 reference

12 December 2020

Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole

1 reference

12 December 2020

10.1007/S40265-013-0013-7

Identifiers

DOI

1 reference

Dimensions Publication ID

1 August 2017

1034446882

0 references

1 reference